This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Steven J. Jacobsen, MD, PhD; Slavica K. Katusic, MD; Erik J. Bergstralh, MS; Joseph E. Oesterling, MD; Del Ohrt, MD; George G. Klee, MD, PhD; Christopher G. Chute, MD, DrPH; Michael M. Lieber, MD

JAMA. 1995;274(18):1445-1449.

Abstract
Objective.
—To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1992 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987.

Design.
—Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time.

Study Setting.
—Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes.

Subjects.
—All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis.

Results.
—The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992.

Conclusion.
—These results support the premise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying more early stage (smaller) cancers.

(JAMA. 1995;274:1445-1449)

Author Affiliations
From the Sections of Clinical Epidemiology (Drs Jacobsen, Katusic, and Chute), Biostatistics (Mr Bergstralh), Health Services Evaluation (Dr Klee), and Medical Information Resources (Dr Chute), Department of Health Sciences Research, Division of Metabolic and Hematologic Biochemistry, and Departments of Laboratory Medicine and Pathology (Dr Klee) and Urology (Drs Oesterling and Lieber), Mayo Clinic and Mayo Foundation, Rochester, Minn; and Blue Cross/ Blue Shield of Minnesota, St Paul (Dr Ohrt). Dr Oesterling is now with the Michigan Prostate Institute, University of Michigan, Ann Arbor.

Footnotes
Reprint requests to Section of Clinical Epidemiology, Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905 (Dr Jacobsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Keeping Our Eye on the Ball: The American Society of Preventive Oncology in 2009
Marshall
Cancer Epidemiol. Biomarkers Prev. 2009;18:2796-2802.
FULL TEXT  

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention
Lucia et al.
Cancer Prevention Research 2008;1:167-173.
ABSTRACT | FULL TEXT  

Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression
Taylor et al.
Mol. Cell. Proteomics 2008;7:600-611.
ABSTRACT | FULL TEXT  

Association of Anthropometric Measures with the Presence and Progression of Benign Prostatic Hyperplasia
Burke et al.
Am J Epidemiol 2006;164:41-46.
ABSTRACT | FULL TEXT  

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial
Andriole et al.
JNCI J Natl Cancer Inst 2005;97:433-438.
ABSTRACT | FULL TEXT  

Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer
Sreekumar et al.
JNCI J Natl Cancer Inst 2004;96:834-843.
ABSTRACT | FULL TEXT  

The complex genetic epidemiology of prostate cancer
Schaid
Hum Mol Genet 2004;13:R103-121.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Screening in Elderly Men
Lu-Yao et al.
JNCI J Natl Cancer Inst 2003;95:1792-1797.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer
Rubin et al.
JAMA 2002;287:1662-1670.
ABSTRACT | FULL TEXT  

NSAIDs and a Lower Risk of Prostate Cancer: Causation or Confounding?
Barry
Mayo Clin Proc. 2002;77:217-218.
 

Hospitalization for Prostate Cancer Among the Older Men in the Longitudinal Study on Aging, 1984-1991
Wolinsky et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M115-121.
ABSTRACT | FULL TEXT  

Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features
Alers et al.
Am. J. Pathol. 2001;158:399-406.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates
Hankey et al.
JNCI J Natl Cancer Inst 1999;91:1017-1024.
ABSTRACT | FULL TEXT  

Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer
Collins et al.
J Law Med Ethics 1997;25:234-242.
 

Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination: Enhancement of Specificity With Free PSA Measurements
Catalona et al.
JAMA 1997;277:1452-1455.
ABSTRACT  

Controversies in Prostate Cancer Screening: Analogies to the Early Lung Cancer Screening Debate
Collins and Barry
JAMA 1996;276:1976-1979.
ABSTRACT  

Predictive Properties of Serum Prostate-Specific Antigen Testing in a Community-Based Setting
Jacobsen et al.
Arch Intern Med 1996;156:2462-2468.
ABSTRACT  

Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen
Smith et al.
JAMA 1996;276:1309-1315.
ABSTRACT  

Questions about the Value of Early Intervention
Welch
NEJM 1996;334:1472-1473.
FULL TEXT  

PSA Screening and Prostate Cancer Incidence
Rhoads and Mills
JAMA 1996;275:1155-1155.
ABSTRACT  

PSA Screening and Prostate Cancer Incidence
Berman et al.
JAMA 1996;275:1155-1155.
ABSTRACT